The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.
ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.
Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.
RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.
BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.
J&J has reported positive topline outcomes from the MARIPOSA trial of RYBREVANT and LAZCLUZE combo for NSCLC treatment.